Dogwood Therapeutics Inc (DWTX)

In the past six months, Dogwood Therapeutics reported its second-quarter 2025 financial results in August 2025, with an EPS of ($1.99) against ($1.15) last year. The company announced the enrollment of the first fifty patients in its ongoing Halneuron Phase 2b trial in August 2025, followed by the enrollment of the first 100 patients by September 2025, with an interim sample size analysis for this trial on track for December 2025, and an interim readout for the Halneuron Phase 2b trial in CINP expected in Q4 2025. In September 2025, Dogwood Therapeutics secured an exclusive worldwide, royalty-free license to develop and commercialize SP16 for cancer-related pain, leading to a significant surge in its stock price, in return for which Serpin Pharma and its designated affiliates received 7.31% of Dogwood's common stock on a fully diluted basis. Dogwood Therapeutics reported its third-quarter 2025 financial results in November 2025, with an EPS of ($8.20), missing the consensus estimate. H.C. Wainwright & Co. maintained a "Buy" rating for DWTX in September 2025 and upgraded it in April 2025, with analysts having a consensus price target of $12.00 for DWTX, representing an upside of 84.05% from its current price. The company announced regaining Nasdaq compliance in April 2025. Dogwood Therapeutics shares underwent a 1-25 reverse stock split on October 9th, 2024.

As a development-stage biotechnology company with products primarily in clinical trials, specific demand seasonality for Dogwood Therapeutics' products and services is not explicitly detailed in the provided information. The available data indicates a "Seasonality Score: 7" and a "Seasonality Move: -29.42%" over the next 52 weeks based on past stock performance, which refers to stock price seasonality rather than product or service demand. Given that its lead candidates are still undergoing clinical evaluation, the company's revenue generation is not yet driven by widespread commercial sales, making traditional product demand seasonality less applicable at this stage.

Dogwood Therapeutics, Inc. is a development-stage biotechnology company focused on creating novel therapies for pain and fatigue-related disorders, operating within the Healthcare sector, specifically in the Biotechnology and Pharmaceutical industries. The company specializes in advancing antiviral therapies to address diseases linked to virus-triggered abnormal immune responses, as well as developing non-opioid pain management solutions. Its key product candidates include IMC-1, a fixed-dose combination of famciclovir and celecoxib, which has completed Phase 2b clinical trials for the treatment of fibromyalgia and is Phase 3 development ready and has been granted fast track designation by the FDA. Halneuron® is a highly selective sodium channel blocker in Phase 2b clinical trials for treating moderate-to-severe chemotherapy-induced neuropathic pain (CINP) and cancer pain, and is also in pre-clinical trials for burn and ocular pain, showing no evidence of addiction, withdrawal symptoms, or euphoria in trials. IMC-2 is a combination of valacyclovir and celecoxib in Phase 2 clinical trials for the treatment of long-COVID and post-acute sequelae of COVID-19 infection. SP16 is an intravenous formulation for the treatment of cancer-related pain and neuropathy, with an early-stage trial fully funded by the National Cancer Institute slated to begin patient enrollment in the first half of 2026. The company was founded in 2012 and is headquartered in Alpharetta, Georgia, United States, formerly known as Virios Therapeutics, Inc., changing its name in October 2024.

Dogwood Therapeutics, Inc. is based in Alpharetta, Georgia, United States. Its former entity, Wex Pharmaceuticals, Inc., was based in Vancouver, British Columbia, Canada, suggesting a North American operational or collaborative presence. The company collaborates with academic institutions and clinical research organizations across North America to support its development efforts.

In the past year, Dogwood Therapeutics' brand reputation appears to be largely influenced by its clinical trial progress and stock performance. Retail sentiment around DWTX stock has been "extremely bullish," and promising clinical trial results have "rejuvenated investor confidence." The company's advancements in its cancer treatment portfolio have been viewed as a significant step forward in oncology, positively impacting market sentiment and confidence in its research capabilities. The National Cancer Institute's funding of the SP16 IV Phase 1b program has also been a positive development, obviating the need for the company to use its existing capital for this program in the near term.

Dogwood Therapeutics is owned by a mix of institutional shareholders, insiders, and retail investors. Approximately 1.70% of the company is owned by institutional shareholders, including Vanguard Group Inc, Geode Capital Management, Llc, and Morgan Stanley. Insiders own approximately 54.05% of the company, with William Pridgen being the largest individual shareholder, owning 34.95% of the company. Retail investors hold approximately 44.25% of Dogwood Therapeutics.